5 completed. 5 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 5 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow Vaccine: new trials by email Literature Review of Vaccine trials Research Report on Vaccine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-Based Anti-Cytomegalovirus (CMV) Vaccine (Triplex®) CMV-MVA Triplex, Placebo - Cytomegalovirus Infections, HIV Infections | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 94 | 2021-11-02 | 2026-10-02 |
| Immunogenicity of COVID-19 Vaccine on Heterologous Schedule Heterologous prime-boost schedule with AZD1222 and MVC-COV1901, Homologous prime-boost schedule with two doses of AZD1222 - Covid-19, Vaccine | Phase 2 | Completed | Chang Gung Memorial Hospital | 100 | 2021-09-15 | 2026-06-15 |
| An Open Comparative Study of the Effectiveness and Incomparable Study of the Immunogenicity and Safety of the Vaccine (CoviVac) for Adults Aged 60 Years and Older CoviVac vaccine (inactivated whole-virion concentrated purified) manufactured by FSBSI "Chumakov FSC R&D IBP RAS" - Corona Virus Infection, Vaccine | Phase 2 | Completed | Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products | 200 | 2021-07-01 | 2026-03-19 |
| Persistence and Long-Term Protection of Vi Antibodies Induced by Vi-DT Conjugate Vaccines in Indonesian Vi-DT Typhoid Conjugate Vaccine - Vaccine | Phase 2 / Phase 3 | Completed | PT Bio Farma | 188 | 2021-05-03 | 2025-06-03 |
| This is a Double-blind, Placebo-controlled, Randomized Study of the Tolerability, Safety and Immunogenicity of an Inactivated Whole Virion Concentrated Purified Vaccine (CoviVac) Against Covid-19 Vaccine for intramuscular injection, Placebo comparator (without active ingredient) for intramuscular injection - Coronavirus Infections, Vaccine | Phase 1 / Phase 2 | Completed | Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products | 400 | 2020-10-03 | 2021-11-12 |
COVID-19 (3) · Coronavirus Infections (2) · Cytomegalovirus Infections (1) · HIV Infections (1)
Infections (4) · RNA Virus Infections (4) · Virus Diseases (4) · Coronaviridae Infections (3) · Lung Diseases (3) · Nidovirales Infections (3) · Pneumonia (3) · Pneumonia, Viral (3) · Respiratory Tract Diseases (3) · Respiratory Tract Infections (3) · Blood-Borne Infections (1) · Communicable Diseases (1) · Coronavirus Infections (1) · DNA Virus Infections (1) · Genital Diseases (1)
ChAdOx1 nCoV-19 (1) · Injections, Intramuscular (1) · MVC-COV1901 vaccine (1) · Vaccines (1)
Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products (2) · Chang Gung Memorial Hospital (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · PT Bio Farma (1)
Russia (2) · Indonesia (1) · Taiwan (1) · United States (1)
Bernie E Medise, MD (1) · Sara Gianella, MD (1)